BioAtla

Historical price data

BioAtla is pioneering a novel class of therapeutics called Conditionally Active Biologics (CABs), designed to be active only in the specific physiological conditions of diseased tissue, such as the acidic, hypoxic tumor microenvironment. This approach aims to unlock previously undruggable targets and improve the safety and efficacy of cancer therapies. The company has built a robust intellectual property portfolio with over 700 patents and applications and is led by a seasoned team with decades of biotech experience. Its strategy focuses on advancing its internal CAB pipeline while exploring potential partnerships for its platform technology.

Proprietary Conditionally Active Biologics™ (CAB) platform that engineers antibodies and other proteins to be functionally active only within the specific physiological conditions (e.g., low pH, hypoxia) of the tumor microenvironment, aiming to improve therapeutic index.

7 drugs in pipeline

Total raised: $495M

BioAtla competes with established ADC developers (e.g., Pfizer, Daiichi Sankyo) and other biotechs with conditionally active therapeutic platforms (e.g., CytomX). Its differentiation is the specific use of tumor microenvironment conditions like pH to control drug activity, a approach that must prove clinically superior to achieve market success.